These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 36534022)
1. Real-world outcomes of Cook Zilver PTX in femoro-popliteal district from multicenter experience. Bianchini Massoni C; Strozzi F; Epifani E; Zenunaj G; Ucci A; Paladini I; Gasbarro V; Tusini N; Freyrie A Int Angiol; 2023 Feb; 42(1):9-18. PubMed ID: 36534022 [TBL] [Abstract][Full Text] [Related]
2. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent. Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions. Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998 [TBL] [Abstract][Full Text] [Related]
4. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease. Tran K; Ullery BW; Kret MR; Lee JT Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688 [TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience. AbuRahma AF; Beasley M; AbuRahma ZT; Davis M; Adams E; Dean LS; Shapiro J; Scott G; Davis E J Endovasc Ther; 2022 Jun; 29(3):350-360. PubMed ID: 34622706 [TBL] [Abstract][Full Text] [Related]
9. Randomized clinical Trial Comparing drug Eluting Stent Zilver PTX® Versus Bare Metal Stent Zilver Flex® for Treatment of Lesions in Femoral and Popliteal Arteries in Chronic Limb Threatening Ischemia. Fransson T; Gottsäter A; Abdulrasak M; Malina M; Resch T Vasc Endovascular Surg; 2023 Oct; 57(7):706-716. PubMed ID: 37085152 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention. Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041 [TBL] [Abstract][Full Text] [Related]
11. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results. Bosiers MJ; De Donato G; Torsello G; Silveira PG; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Eckstein HH; Teβarek J; Giaquinta A; van den Eynde W; Verbist J; Callaert J; Deloose K; Bosiers M Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1348-1358. PubMed ID: 37670198 [TBL] [Abstract][Full Text] [Related]